Background. Preclinical experiments have shown that donor blood cells, modified in vitro by an alkylating agent (MIC, modified immune cells), induced long-term specific immunosuppression against the allogeneic donor.
Introduction
Long-term renal allograft survival is limited for two reasons: firstly, conventional immunosuppression is not capable of preventing chronic rejection which is responsible for more than half of graft losses, and secondly, conventional immunosuppressive therapy has serious side effects leading to increased morbidity and even death of patients with functioning allografts (1, 2) . Therefore, there is a great need for an anti-rejection therapy with fewer side effects and greater efficacy. The ideal would be donor-specific immunosuppression in the absence of systemic down-regulation of the immune response.
Cellular therapies are gaining increasing attention as an alternative to conventional drug therapy for the control of allograft rejection (3) . Effective rejection prophylaxis in the absence of immunosuppressive drugs has been achieved by establishing durable hematopoietic chimerism through combined or sequential hematopoietic stem cell application in kidney transplantation (4) (5) (6) (7) . The administration of hematopoietic stem cells, however, is an intervention that is limited by the toxicity of the conditioning regimen, the occurrence of graft versus host disease, and the need for a human leukocyte antigen (HLA) well-matched donor.
Mixed chimerism was preferred to full donor chimerism as a means of inducing transplant tolerance because it offers greater safety. However, mixed donor chimerism was often temporary, therefore limiting its efficacy, but still associated with the risk of graft versus host disease (8) . More recently, regulatory cell populations such as regulatory T lymphocytes have been evaluated for the prevention of kidney transplant rejection in preclinical models and are currently being tested in clinical trials (9) .
We have developed a cell therapeutic called MIC (modified immune cells) that, when injected into the recipient before transplantation, was capable of inducing donor-specific immunosuppression in various animal models such as rat heart and hind-limb transplantation, or pig kidney transplantation (10, 11) . MIC were also effective in reversing a severe 6 refractory rejection episode after allogeneic hematopoietic stem cell transplantation during emergency treatment in a pediatric patient (10) .
In previous studies we focused on the phenotypic and functional characterization of MIC.
When monocytes were treated with the alkylating agent mitomycin C and then matured to dendritic cells (DC), the resulting cells showed the morphology and phenotype of early immature DC and strongly suppressed the T cell response. Fluorescence-activated cell sorting (FACS) analysis revealed low expression of stimulatory molecules, such as CD80, CD83, CD86 and HLA-DR (12) . When injected into the prospective experimental graft recipient, donor-derived MIC preferentially accumulated in peripheral lymphoid organs and induced regulatory lymphocytes (10) .
Our aim was to translate the findings from preclinical experiments to a clinical phase-I study in living donor kidney transplantation.
Results

Outcomes during study phase
This was a 30-day single-arm, single-center phase-I clinical trial for the determination of safety and feasibility of the intravenous administration of donor-derived MIC for individualized immunosuppression in living donor kidney transplant recipients. From August 2015 to February 2017, 14 donor (D) and recipient (R) pairs were screened for inclusion into the TOL-1 study (Supplemental Figure 1 ). Baseline characteristics of patients are shown in Table 1 and Supplemental Table 1 . The MIC product was eventually administered intravenously to 10 patients (R1-R7, R11, R12, R14) on the day of donor leukapheresis and product preparation as a one-time administration. Patients received a prescribed dose of either 1.5x10 6 MIC per kg b.w. on day -2 (N=3, group A), or 1.5x10 8 MIC per kg b.w. on day -2 (N=3, group B) or day -7 (N=4, group C) before living donor kidney transplantation in addition to post-transplant immunosuppression with cyclosporine A (CyA), enteric-coated mycophenolate sodium (EC-MPS) and methylprednisolone. The TOL-1 study design is depicted in Figure 1 .
Data collected during the first 30 days after transplantation showed that MIC infusions were extremely well tolerated. A total of 69 adverse events (AE) including 3 serious AE (SAE) occurred in the 10 treated patients ( 
No detectable donor chimerism after MIC infusion
One day after MIC infusion, no donor chimerism was detectable in the 10 patients (Supplemental Table 5 ). Absence of donor chimerism was further confirmed on day -1 before and on days 7 and 30 after transplantation. As expected from chimerism analyses, none of the patients showed clinical evidence of graft-versus-host disease during follow-up.
Clinical outcomes up to one year after transplantation
After the study endpoint on day 30, patients were followed to day 360 after kidney transplantation. Immunosuppressive therapy in patients of group C was reduced to lower CyA and lower EC-MPS with or without corticosteroids (Supplemental Figure 3 ). During followup, no de novo DSA or rejection episodes occurred and all patients had stable kidney graft function ( Table 3 , Supplemental Table 4 , Supplemental Figure 2 ). On day 360 after surgery, the median serum creatinine was 1.4 mg/dL (1.1-2.1), median estimated glomerular filtration rate (eGFR) 58 mL/min/1.73m 2 (37-75) and median urinary protein excretion 10 g/moL creatinine (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . No opportunistic infections occurred. In particular, no BKV replication was observed during rigorous post-transplant screening. A total of 10 non-opportunistic infectious episodes occurred in 4 of the 10 patients (Table 3) . No post-transplant diabetes mellitus (PTDM), leukopenia, episode of diarrhea, post-transplant lymphoproliferative disease (PTLD) or other malignancies were observed. The total antihypertensive therapeutic intensity score was lower on day 360 after transplantation than before surgery, particularly in patients of group C, and normal blood pressure was maintained in all patients.
Based on previous experimental studies, it was expected that treatment with the highest MIC cell number 7 days before transplantation would induce the strongest donor-specific immunosuppression. Therefore, detailed immunological testing was performed in patients of group C (R7, R11, R12, R14) whose MIC administration protocol corresponded to this schedule and who were on low immunosuppression.
Anti-donor T lymphocyte responses in MIC-treated patients
Patients from group C showed preserved lymphocyte proliferation in response to unspecific polyclonal stimulators on day 360 after transplantation as compared to before MIC infusion, indicating an intact general immune response (Figure 2A ). This was confirmed by allogeneic stimulation with third party cells ( Figure 2B ). In contrast, the T-cell response against the respective specific donor was absent on day 360 as compared to before MIC infusion ( Figure   2B ). Five out of 6 transplanted controls who were not treated with MIC showed normal Tlymphocyte reactivity to cells derived from their respective donors ( Figure 2C ), even though these patients were still on triple immunosuppressive therapy. Figure 2D -G shows the response of individual patients before (days -7, -6, -1) and after transplantation (days 7, 30, 60, 90, 135, 180, 270, 360). Pre-transplant data include values before (day -7) and after MIC therapy (days -6, -1). The measurement in patient R7 showed reduced responsiveness to the donor with preserved responsiveness to third party cells one day after MIC administration. This effect was maintained throughout follow-up ( Figure 2D ).
In contrast, in patient R11 high proliferation in response to the donor was found 6 days after MIC therapy during an upper respiratory tract infection, and on day 180 after urinary tract infection with severe allergic reaction to a quinolone antibiotic ( Figure 2E ). A similar reaction was found in patient R12 on day 180 after pneumonia and urinary tract infection ( Figure 2F ).
In both patients, R11 and R12, the anti-donor response disappeared completely during further follow-up with preserved responsiveness to third-party cells. Patient R14 had an increased response to the donor on day 90 ( Figure 2G ). This was at the time of steroid withdrawal and 2 weeks before some deterioration of kidney graft function was observed. The kidney graft biopsy, however, showed no abnormality (Supplemental Table 4 ) and responsiveness to the original donor disappeared during further clinical course without additional treatment. Of note, from day 270 after transplantation onward, all patients showed a completely suppressed T lymphocyte response to the donor, with normal reactivity against third party cells.
HLA antibodies and antibody titers to bacterial and viral immunizations
During follow-up no de novo DSA were detected (Table 3 ). This finding raised the question of whether the memory B cell response to donor-unrelated antigens as induced by previous immunizations was also affected. Antibody titers against measles (median 4400 mIU/mL, 200-11,000), mumps (median 400, 230-8000), rubella (median 41 IU/mL, , varicella (median 1350 mIU/mL, 410-3500), diphtheria (median 0.17 IU/mL, 0.04-0.33), and tetanus (median 1.5 IU/mL, 0.5-2.1) were lowest on day 30 after transplantation, but reached pretransplant levels during further follow-up (Supplemental Figure 4 ).
Levels of T lymphocyte-, B lymphocyte-and NK cell numbers
The numbers of CD4 + and CD8 + T lymphocytes as well as of activated CD4 + and CD8 + T lymphocytes remained stable before and after transplantation (Supplemental Figure 5A Figure 5E ). CD16 + CD56 + NK cells behaved inversely, being lowest on day 30 post-transplant with a median of 60/µL (33-73) but increased to a median of 104/µL (93-154) on day 180 (Supplemental Figure 5F ).
Unchanged regulatory T lymphocyte frequencies
The percentage of CD4 + CD25 + FoxP3 + CD127regulatory T lymphocytes (Treg) was low on day 30 after transplantation ( Figure 3 ) during the period of potent immunosuppressive therapy. The median percentage increased from 1% (0-1) on day 30 to 3% (1-5) on day 180 ( Figure 3B ). This value was comparable to the pre-transplant and pre-treatment level of 3% (2) (3) (4) .
Strongly increased regulatory B lymphocyte frequencies
Interestingly, the percentage of CD19 + CD24 high CD38 high transitional B lymphocytes (regulatory B lymphocytes, Breg) was low until day 30 after transplantation with a median of 2% (0-6, Figure 4B ) but showed a striking increase thereafter. Breg increased to a median of 20% (5-40) on day 180, exceeding by far the pre-transplant levels which showed a median of only 6% (0-11) before MIC infusion. Not only the relative proportion but also absolute Breg numbers increased from a median of 4.5/µL (0.3-15) on day 30 to 10/µL (3.8-15) on day 180 (data not shown).
Breg percentages in patients of group C in comparison to Breg percentages of transplanted controls without MIC infusion are shown in Figure 4C . Before MIC infusion, the values were comparable between patients of group C and transplanted controls with a median of 6% versus 11%, respectively. In contrast, in MIC-treated patients Breg dramatically increased post-transplant and were 4, 3, 9, 19, 26, and 13 times higher than in transplanted controls on days 60, 90, 135, 180, 270, and 360 after transplantation, respectively. Patient R11, who was treated with high-dose methylprednisolone due to an allergic reaction against a quinolone antibiotic, showed a lower 5% of Breg on day 180. Even this percentage was 5 times higher than in transplanted controls (day 180: median 1%, 0-2). In this patient, Breg increased subsequently to reach 13% on day 720 (Supplemental Figure 6 ).
To further exclude a decisive effect of steroids on the observed differences in Breg percentages, we compared MIC-treated patients of group C to a second independent cohort of transplanted controls without MIC infusion who were stratified according to methylprednisolone dose ( Figure 4D ). Breg in group C patients were 68 and 44 times higher than in transplanted control patients without steroid treatment 180 and 360 days after transplantation, respectively. At last follow-up (median 810 days, 720-1080) after transplantation and more than 1.5 years after steroid withdrawal in all MIC-treated group C patients, Breg showed a median of 7% (5-11) and were 24 times higher than in transplanted controls without steroid treatment. The Breg were also higher than the 2% Breg in a control patient with operational tolerance from our center ( Figure 4D , Supplemental Figure 6 ).
It was of particular interest whether Breg also increased in patients of groups A (receiving a reduced cell dose on day -2) and B (receiving the full cell dose on day -2). For this purpose, we analyzed Breg from frozen samples in groups A, B, and C. As expected from preclinical experiments, patients from group C showed the highest Breg percentages exceeding the values in patients of groups A and B by a factor of 68 and 20, respectively, on day 180 after transplantation ( Figure 4E ). Figure 4F , the majority of Breg from patients of group C produced the immunosuppressive cytokine IL-10 (median of 44-100%).
As shown in
High levels of immunosuppressive cytokines IL-10 and TGF-β1
Supplemental Tables 6 and 7 list 20 serum protein expressions with the largest decreases/increases in all 10 patients after (day -1) as compared to before (day -2/-7) MIC administration. The most intriguing findings were the strong decrease of HLA class II histocompatibility antigen and the increases of IL-10 and TGF-β1 (Supplemental Tables 6, 7, Ingenuity pathway analysis (IPA) of proteome data after as compared to before MIC administration pointed to 23 biological functions that were significantly upregulated and two 13 that were downregulated. Of the downregulated functions, suppression of immunological disease/hypersensitive reaction was of special interest in the context of transplantation ( Figure   5 ).
Patients display an Immune Tolerance Network operational tolerance signature after MIC infusion
Since IL-10 producing Breg were associated with operational tolerance, the Immune Tolerance Network operational tolerance signature was tested in group C and compared with group A and B patients who lacked the remarkable increase in Breg frequencies. Though displaying some overlap with the other groups, the strongest expression of IGKV4-1 and IGKV1D-13 on day 180 was found in group C (Supplemental Figure 8 ).
Discussion
The primary objective of this phase-I clinical trial was to establish non-toxicity. MIC infusions were extremely well tolerated with no infusion-related side effects. None of the 10 patients developed de novo DSA or rejection episodes even though they received up to 1.3x10 10 of allogeneic donor mononuclear cells before transplantation.
Since some results were obtained that went beyond a classical safety study, we were encouraged to discuss these data with regard to a possible efficacy of MIC therapy. Naturally, definitive conclusions cannot be drawn at this time. Group C patients received the highest cell dose 7 days before surgery and were on low immunosuppression during follow-up. They showed absence of post-transplant cellular stimulation reactivity when tested against their respective kidney donors, whereas reactivity against third party cells was retained. These patients also showed strong Breg induction with concomitant IL-10 production, and suggestive evidence of an immune tolerance signature as per definition of the Immune Tolerance Network. Taken together with results obtained in our previous experimental studies, these data support the idea that donor-specific immunosuppression was induced by MIC treatment (10) (11) (12) .
It is interesting that common infections, like upper respiratory tract or urinary tract infection, triggered off transient donor-specific responsiveness that disappeared again after resolution of the infection. From day 270 onward to the most recent follow-up (median 810 days, 720-1080) after transplantation, all patients showed a continued completely suppressed T lymphocyte response to the specific donor (data not shown).
An exciting observation in MIC-treated group C was the strong increase of CD19 + CD24 high CD38 high transitional B lymphocytes (Breg) after transplantation. Transitional CD19 + B-cells characterized by surface expression of CD24 hi CD38 hi have been proposed as tolerance markers due to data supporting their role in maintaining long-term allograft acceptance (13) (14) (15) (16) (17) (18) . Preserved levels of CD19 + CD24 high CD38 high transitional B lymphocytes were described in operationally tolerant patients in a range of 4-7% (14) . Tebbe et al. found in patients receiving routine doses of immunosuppression with CyA as a calcineurin inhibitor CD19 + CD24 high CD38 high transitional B lymphocyte frequencies in the range of 0-5% during the first year after transplantation. Those patients who showed frequencies greater than 1% developed no rejection episodes (17) . In our study, the Breg frequencies of transplanted controls who were not subjected to MIC conditioning were comparable to the rates described by Tebbe et al., whereas the patients in MIC-treated group C showed frequencies in the range of 5-40% (median 20%) on day 180 after transplantation, exceeding by far the values of transplanted controls (day 180: median 1%) and those found in these group C patients before transplantation (day -7: median 6%).
Breg modulate the effector function of both adaptive and innate immune cells (19) . The suppressive function of Breg is thought to be mediated in part by IL-10 (20) . We found that the great majority of Breg in MIC-treated group C patients produced IL-10. This finding was further substantiated by the observation that IL-10 levels in the sera of these patients were increased.
Recent data suggest that type and dose of immunosuppressive therapy may interfere with the induction of CD19 + CD24 high CD38 high transitional B lymphocytes (Breg) (21, 22) . In a crosssectional study of 117 transplant recipients, Bottomley et al. found no significant association between steroids and Breg (21) , while in the GAMBIT study Rebollo-Mesa et al. observed slightly higher Breg percentages in patients with reduced or no steroids (22) .To address this issue, we identified transplanted control patients on immunosuppressive therapy comparable to that of MIC patients and analyzed their Breg frequencies retrospectively. Impressively, on day 135 after transplantation and before steroids were stopped in 3 out of 4 group C patients, Breg percentages were already 9-fold higher than those in transplanted controls. At last follow-up, more than 1.5 years after steroid withdrawal in all MIC-treated group C patients, Breg were 24-fold higher than in a second independent cohort of transplanted controls without steroid treatment, and considerably higher than the Breg percentage in a control patient with operational tolerance from our center. Data that also argue against an overriding interference of immunosuppressive medication were derived from our current studies in a murine model of lupus nephritis. MIC-treated animals showed significantly higher Breg (CD19 + CD5 + CD1d high ) frequencies than untreated controls in the absence of any immunosuppressive therapy (Claudius Speer, unpublished observations).
Studies on CD34 + stem cell transplantation reported donor-specific unresponsiveness when persistent chimerism was established (23, 24) . In HLA identical living donor kidney transplant recipients, complete withdrawal of immunosuppressive therapy was feasible without allograft rejection even when chimerism was lost during the further course (25) . We learned from our preclinical studies that long-lasting chimerism is not established after MIC treatment. After infusion, MIC immediately left the circulation and preferentially accumulated in the spleen of treated rats where they were detectable for a maximum of 7 days (10, Christian Kleist, unpublished observations). Impressively, when peripheral blood mononuclear cells (PBMC) from MIC-treated animals were later transferred to naïve rats, those rats tolerated heart allografts from the original MIC donor strain but not from third party (10) . This indicates the induction of regulatory cell populations in treated animals during the short contact of the recipient´s immune system with donor-MIC. In line with these observations, MIC-treated group C patients established no donor chimerism at a 1% detection limit of the assay while Breg were detectable at high percentages throughout follow-up.
A limitation of this study is the absence of surveillance biopsies beyond day 7 after transplantation to rule out alloimmune injury such as sub-clinical T-cell-mediated inflammation. CyA was chosen rather than tacrolimus because it represented the standard calcineurin inhibitor for unsensitized kidney recipients in our center at the time of the study, and since no interference of CyA with MIC treatment was found during preclinical experiments (26) . We speculate that tacrolimus will provide similar results. In favor of this assumption are the results of a recent study showing that the Breg levels in stable immunosuppressed patients on tacrolimus were even higher than the levels in patients on CyA (17) . We recognize the limitations of data obtained in a phase-I clinical trial and particularly in this trial in which only 4 patients received the full MIC cell dose on day -7. Clearly, the observations described in this report are preliminary. Nevertheless, their exciting nature motivated us to submit this report at this time because we believe it will stimulate many workers in the immune tolerance field to conduct work that builds on these preliminary observations.
In summary, MIC therapy was well tolerated in this phase-I clinical trial and did not lead to humoral sensitization or rejections. The in vitro findings of an absence of specific cellular stimulatory reactivity against donor cells post-transplant, paralleled by a rise in Breg and IL-10 levels, lead us to hypothesize that MIC conditioning may constitute a promising method for inducing donor-specific immunosuppression in renal transplantation. There is a suggestion but it is much too early to know whether this treatment is sufficiently tolerogenic to allow complete withdrawal of immunosuppression. The preliminary phase-I results, however, are sufficiently encouraging to proceed with phase-II and -III clinical trials.
Methods
Study protocol
We The MIC product was eventually administered intravenously to 10 patients (R1-R7, R11, R12, R14) on the day of donor leukapheresis and product preparation as a one-time administration.
Patients were excluded for the following reasons: Patient R8 was found to have a dissection of the right iliac and femoral artery during pre-transplant CT scan evaluation. The evaluation had already been performed before screening but dissection became obvious only after screening.
In patient R9, acute hyperthyroidism was diagnosed during visit V2. Transplant surgery had to be postponed in both patients. During screening, patient R10 was found to have a positive IgM XM One crossmatch (Olerup, Stockholm, Sweden) result and patient R13 was found to have irregular warm-reacting antibodies during visit V2. Though no formal contraindications for inclusion into the study, we decided not to perform cell therapy in either patient for safety reasons. Transplant surgery was performed as scheduled but outside the TOL-1 study. Two donors (D8 and D10) were screened but received no leukapheresis for cell harvesting since the corresponding recipients were excluded from the study. Leukapheresis was performed in donor D9 and D13 but cells were not further processed and were discarded for the reasons outlined above. In these donors, the study was finished per protocol with visit V3 on the day after leukapheresis.
Patients were treated sequentially in a stepwise approach with dose escalation from group A (1.5x10 6 Post-transplant recipient visits were on days 7±1 (V4, including a protocol biopsy procedure) and 30±4 (V5, end of study).
Maintenance immunosuppressive therapy and post-transplant care were performed according to center practice with CyA, EC-MPS and methylprednisolone given from the day of surgery.
The detailed immunosuppressive therapy in patients is depicted in Supplemental Figure 3 .
Antibody induction therapy with IL-2 receptor antagonist was not performed in MIC-treated patients since IL-2 receptor signaling is believed to be critical for the development and expansion of regulatory cells (27) .
Follow-up period and transplanted controls
After the study endpoint on day 30, patients were followed to day 360 after kidney transplantation with regular outpatient visits according to center practice. Routine screening was performed for BKV (on every outpatient visit during year 1), and DSA (days 7, 30, 180, 
Further investigations
Immunological testing, quantitative chimerism analysis in peripheral blood, proteomic analysis of patient serum samples and gene expression analysis from peripheral blood were performed as described in detail in the Supplemental Methods.
Statistics
Due to the small number of patients and the exploratory approach of the trial, only descriptive statistical methods were applied. In the text and tables, continuous data are summarized as median and range, categorical data as absolute and relative frequencies. Longitudinal data are Co-first authorship of CM and ASch and co-senior authorship of MScha and PT as well as the respective order had already been defined in the clinical study protocol. At day -2 (groups A and B) or -7 (group C) before kidney transplantation, peripheral blood mononuclear cells (PBMC) were collected from donors by unstimulated standard leukapheresis. PBMC were transferred to the Good Manufacturing Practice (GMP) facility and incubated with the proliferation inhibitor mitomycin C. After washing out of mitomycin C and quality control, the final product (modified immune cells = MIC) was administered to patients on the same day about 12 hours after donor leukapheresis. Patients received either 1.5x10 6 MIC per kg b.w. on day -2 (N=3, group A), or 1.5x10 8 MIC per kg b.w. on day -2 (N=3, group B) or day -7 (N=4, group C) before living donor kidney transplantation intravenously on an intensive care unit. After transplantation, patients received immunosuppressive therapy with cyclosporine A, enteric-coated mycophenolate sodium and corticosteroids according to center protocol. Primary outcome measure was the frequency of adverse events on day 30 (end of study). . IL-10 production of CD19 + CD24 high CD38 high transitional B lymphocytes was further investigated using a CD38/IL-10 gate based on gate R6. (B) Individual measurements for percentage of CD19 + CD24 high CD38 high Breg in patients R7 (■), R11 (♦), R12 (▲), R14 (•) from day -7 to day 360 are shown. CD19 + CD24 high CD38 high Breg were low to day 30 after kidney transplantation and increased to day 180. (C) Individual measurements for percentage of CD19 + CD24 high CD38 high Breg in patients of group C (•) were compared to measurements in transplanted controls (•). Individual measurements and median are shown. Compared to transplanted controls, Breg were 4, 3, 9, 19, 26 , and 13 times higher in patients of group C on day 60, 90, 135, 180, 270, and 360 after transplantation, respectively. (D) Individual measurements for percentage of CD19 + CD24 high CD38 high Breg in patients of group C were compared to measurements in a second independent cohort of transplanted controls stratified according to steroid dose (given in brackets). Individual measurements and median are shown. Compared to transplanted controls without steroid treatment, Breg were 68 and 44 times higher in patients of group C on day 180 and 360 after transplantation, respectively. (E) Percentage of CD19 + CD24 high CD38 high Breg in frozen cells from patients of groups A-C. Median and interquartile range is shown. In contrast to CD19 + CD24 high CD38 high Breg from groups B and C, Breg from group A were 68 and 20 times higher, respectively, on day 180 after transplantation. (F) Percentage of IL-10 producing Breg. Individual measurements and median are shown for cumulative post-transplant data from patients of group C. The majority of Breg was producing the immunosuppressive cytokine IL-10.
Figures and Figure Legends
Figure 5: Immune reaction patterns induced by MIC therapy based on proteome analysis
Ingenuity pathway analysis (IPA) of proteome data on day -1 (after MIC infusion) versus day -2/-7 (before MIC infusion) indicates significant downregulation of the biological function immunological disease/hypersensitive reaction after MIC administration but before kidney transplantation and application of immunosuppressive therapy. Upregulated (•), downregulated (•), predicted inhibition (■), leads to activation (▬), leads to inhibition (▬), findings inconsistent (▬), or not predicted (▬) Abbreviations: CD74 = HLA class II histocompatibility antigen gamma chain (HLA-DR), IL10 = interleukin 10, MMP3 = Stromelysin-1, PTPRC = receptor-type tyrosine-protein phosphatase C, SDC1* = Syndecan-1, SPP1 = Osteopontin, TGFB1 = Transforming growth factor beta-1, TNF = Tumor necrosis factor, TNFRSF8 = Tumor necrosis factor receptor superfamily member 8 (CD30), VDR = Vitamin D3 receptor, CD2 = T-cell surface antigen CD2. Table 1: 
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